Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancer

Dr Sara Tolaney joins touchONCOLOGY to discuss the latest clinical trial highlights in breast cancer, at ESMO 2022. She discusses the overall survival data from the TROPiCS-02 study, investigating sacituzumab govitecan-hziy versus treatment of physician’s choice in participants with HR+/HER2- metastatic breast cancer; and the overall survival data from the phase 3 MONARCH 3 trial, investigating abemaciclib plus an NSAI in patients with HR+, HER2- advanced breast cancer.

Catch up on Dr Sara Tolaney’s summary of the AMEERA-3 phase 2 study – Amcenestrant vs. endocrine treatment in patients with endocrine-resistant ER+/HER2− advanced breast cancer

Question:

1. What are the hot topics and highlights in breast cancer from ESMO 2022?

Disclosures: Sara Tolaney is a consultant for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Chugai Pharmaceuticals, Myovant, Zetagen, and Umoja Biopharma; and also receives grant/research support from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Sanofi, and Seattle Genetics.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more breast cancer content here